发明名称 BETA-AMYLOID-ANALOGUE - T-CELL EPITOP VACCINE
摘要 Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous APP or A.beta., said analogues being capable of inducing antibody production agains t the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of o ne single or a few foreign, immunodominant and promiscuous T-cell epitopes. Als o disclosed are nucleic acid vaccination against APP or A.beta. and vaccinatio n using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
申请公布号 CA2457140(A1) 申请公布日期 2004.02.27
申请号 CA20022457140 申请日期 2002.08.20
申请人 PHARMEXA A/S 发明人 RASMUSSEN, PETER BIRK;DEGAN, FLORENCE DAL;KOEFOED, PETER;NIELSEN, KLAUS GREGORIUS;JENSEN, MARTIN ROLAND
分类号 C12N15/09;A61K;A61K35/74;A61K35/76;A61K38/00;A61K39/00;A61K39/02;A61K39/10;A61K39/12;A61K39/385;A61K39/39;A61K39/395;A61K45/06;A61K48/00;A61P;A61P3/10;A61P25/00;A61P25/14;A61P25/16;A61P25/28;C07K;C07K14/47;C07K19/00;C12N1/15;C12N1/19;C12N1/21;C12N5/10 主分类号 C12N15/09
代理机构 代理人
主权项
地址